Skip to content
Research Article Open access CC BY 4.0

Dipeptidyl Peptidase - 4 Inhibitors - An Overview of the Combination of These Molecules and Hypoglicemic Oral Drugs

Cristina Iancu, Oana Cioancă, Madalina Mocanu, Flavia Burlec, Andreea Corciovă, Nina Filip, Monica Hăncianu, Cornelia Mircea

Journal of Pharmaceutical Research International · pp. 8–14 · Published 9 Mar 2022

10.9734/jpri/2022/v34i20A35820

Abstract

The purpose of the current review is to bring up to date some studies and data about the effects of hypoglycemic oral drugs in combination with DPP-4 inhibitors. As the medicine and pharmaceutical industry are revolutionary in type 2 diabetes protocols, scientists made a close research on patients that have combined metformin plus sulfonyurea and metformin plus DPP-4 inhibitors. Statistics showed that sulfonylurea compared to DPP-4 inhibitors, in combination with metformin, increased the risk of severe hypoglycemia, fatal and nonfatal cardiovascular diseases, and mortality. Another important discovery showed that the insulin associated with metformin increased the risk of all-caused mortality, compared with the DPP-4 inhibitors plus metformin.

Dipeptidyl peptidase - 4 inhibitor type 2 diabetes oral drugs

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.